Merck's drug, molnupiravir, developed with Ridgeback Biotherapeutics, was shown to reduce COVID-19 hospitalizations and deaths by around 30 per cent.

An authorization from the U.S. Food and Drug Administration could help change clinical management of COVID-19 as the pill can be taken at home.